Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

William D Figg

Senior Investigator, Lab Chief, Associate Director

National Institutes of Health

United States

Research Interests

Explore related searches

Professors in United States Professors in Biochemistry Biochemistry professors in United States

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Collaborators (12)

David R Mole

University of Oxford

UNITED KINGDOM

View details

Xin Wei Wang

Acting Chief

National Cancer Institute

UNITED STATES

View details

Firouzeh Korangy

National Institutes of Health

UNITED STATES

View details

Bjoern Buehring

Ruhr-Universität Bochum

GERMANY

View details

Marie Galligan

University College Dublin

IRELAND

View details

Peter Ratcliffe

Principal Group Leader

University of Oxford

UNITED KINGDOM

View details

Eric S. Schafer

UNITED STATES

View details

Michael Carducci

Vice Chair, Solid Tumor Oncology

Johns Hopkins University

UNITED STATES

View details

Peter Horby

Professor of Emerging Infectious Diseases

University of Oxford

UNITED KINGDOM

View details

Jordan Meier

National Institutes of Health

UNITED STATES

View details

Susan E Bates

Columbia University Irving Medical Center

UNITED STATES

View details

James Gulley

Co-Director

National Cancer Institute

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

William D Figg

Research Interests

Explore related searches

Articles (20)

Hypoxic regulation of chromatin and gene transcription

Intermittent enzalutamide in recurrent prostate cancer: testosterone kinetics and related toxicity

Targeting the PI3K/AKT pathway in prostate cancer: the role of PTEN deficiency and biomarker-guided therapy

Sociodemographic trends in prostate cancer: insights from the All of Us Research Program

Multiomics analysis of immune correlatives in hepatocellular carcinoma patients treated with tremelimumab plus durvalumab

Tecovirimat for Clade I MPXV Infection in the Democratic Republic of Congo.

Targeting NAD<SUP>+</SUP> Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82

Vincristine Sulfate Liposome Injection With Combination Chemotherapy for Children, Adolescents, and Young Adults With Relapsed Acute Lymphoblastic Leukemia: A Therapeutic Advances in Childhood Leukemia and Lymphoma Consortium Trial

National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations

Recent Advances in Bioanalytical Methods for Quantification and Pharmacokinetic Analyses of Antibody–Drug Conjugates

Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7-Expressing CRPC Models.

Vaping and cancer metastasis: novel preclinical insights and results from the All of Us Research Program

Clinical trial results: each patient's participation should count.

A phase 2 study of single agent ibrutinib for first-line treatment of chronic graft-versus-host disease: A new paradigm and lessons learned.

Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation.

Sustained Interferon Signature Suppression With Anifrolumab in a Patient With STING-Associated Vasculopathy with Onset in Infancy Refractory to JAK Inhibitor and Dazukibart Therapy.

Genomic alterations and transcriptional phenotypes in circulating free DNA and matched metastatic tumor.

Requests to Be a Content Expert Reviewer for Journals I Am Not Affiliated With: A Major, Ongoing Problem for the Academic Community.

Navigating the oncology drug discovery and development process with programmes supported by the National Institutes of Health.

Multi-Component, Time-Course screening to develop combination cancer therapies based on synergistic toxicity.

Collaborators (12)

David R Mole

Xin Wei Wang

Firouzeh Korangy

Bjoern Buehring

Marie Galligan

Peter Ratcliffe

Eric S. Schafer

Michael Carducci

Peter Horby

Jordan Meier

Susan E Bates

James Gulley

Make your next move.